FEBS Letters is one of the world's leading journals in biochemistry and molecular biology and is renowned both for its quality of content and speed of production. Bringing together the most important developments in the molecular biosciences, FEBS Letters provides an international forum for Minireviews, Research Letters and Hypotheses that merit urgent publication.
FEBS Letters offers:
- Fast turnaround. Papers that do not qualify for review are returned to the author within 2 days from submission. Average time to first decision is 2.3 weeks. Accepted papers appear online within 5 days. The print version of the article is published in 3 to 5 weeks after acceptance. Articles in Press are included in PubMed.
- Fair and competent peer review. All FEBS Letters articles are peer reviewed by highly qualified scientists. The journal’s Reviewer database includes over 30000 scientists from all over the world. Special attention is paid to conflicts of interest.
- Edited by specialists in the field. Manuscripts are directly handled by Academic Editors, who are highly ranked scientists that regularly publish in a related field.
- Transparency. Manuscripts can be easily tracked throughout the review process. Authors are welcome to openly discuss problems with the Editor. Editor names are published on the article front page. Author contributions are mentioned on the published article.
- Easy-to-use online submission system. The journal offers a user-friendly online submission system, which allows authors to submit their manuscript as a single file for the initial peer review process.
- Free access for all reviews. All FEBS Letters Reviews, Hypotheses and Special Issues are immediately made freely available, at no extra cost for the authors. In addition, a small selection of high quality Research Letters are also made freely accessible as a means to promote good research.
- Fast track option. FEBS Letters offers expedited handling of manuscripts that have been rejected from high-level journals with reviews. A final decision is reached within a week from submission.
- Open Access options. FEBS Letters is a hybrid open access journal and offers authors the option to sponsor non- subscriber access to their articles on Wiley Online Library.
- Longevity The cited half-life of FEBS Letters articles is >10 years.
- No page charges and free color figures.
- FEBS is not for profit. FEBS is one of the largest not-for-profit organizations in life sciences today. The income generated by FEBS Letters is reinvested in science to support fellowships, advanced courses and the annual FEBS Congress.
Aims and Scope
The subject area of FEBS Letters covers all the basic molecular biosciences inherent to microbes, plants and animals in health and disease. To enhance visibility of published articles in different fields, the journal is now subdivided into the following sections:
Bioenergetics; Biophysics; Cell fate determination (cell cycle, cell differentiation, cell death); Chemical Biology; Computational Biology (genomics, proteomics, bioinformatics); Cytoskeleton; Development; Enzymology; Evolution; Genome organization and stability; Glycobiology; Immunology; Membrane Biology (membrane trafficking, vesicles, organelles); Metabolism; Microbiology; Molecular basis of disease; Neuroscience; Plant Biology; Protein Chemistry; Protein Homeostasis; Redox Biology; Regulation of gene expression; RNA Biology; Signal Transduction; Structural Biology; Synthetic Biology; Systems Biology; and Virology.
Research Letters should be short but complete and essentially final reports providing molecular mechanistic insight. Methodological papers are considered for publication only when they are truly novel and significant, and interesting to a broad readership.
- The 2016 FEBS Letters Crossword Challenge now solved!
Please click on the link above to access The FEBS Letters Crossword with clues based on the 2016 Editors’ Choices, and scroll down for the solutions.
- We congratulate FEBS Letters author Prof. Yoshinori Ohsumi on winning the 2016 Nobel Prize in Physiology or Medicine
- Read the celebratory FEBS Letters Virtual Issue "Autophagy: The 2016 Nobel Prize" collecting elegant studies on autophagy performed by Yoshinori Ohsumi and his coworkers